| Literature DB >> 25886604 |
Suji Kim1, Seok-Jae Kang2, Ki-Wook Oh3, Byung Kyu Ahn4, Hang Lak Lee5, Dong Soo Han6, Kiseok Jang7, Young Seo Kim8.
Abstract
BACKGROUND: Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare complication of Crohn's disease (CD), and it is uncertain whether it is associated with CD itself or with its treatment. We describe a case of CIDP-like neuropathy as an initial symptom of CD. The neurologic symptoms of the patient which responded partially to intravenous immunoglobulin (IVIG) recovered after resection of the appendiceal CD. CASEEntities:
Mesh:
Substances:
Year: 2015 PMID: 25886604 PMCID: PMC4379591 DOI: 10.1186/s12883-015-0302-8
Source DB: PubMed Journal: BMC Neurol ISSN: 1471-2377 Impact factor: 2.474
Serial nerve conduction study findings
|
|
|
|
|
|
|---|---|---|---|---|
| Median motor, right | ||||
| CMAP amplitude (mV) | 6.1 |
|
| 5.1 |
| Distal latency (m/s) |
|
|
|
|
| NCV (m/s) |
|
|
|
|
| F-wave latency (m/s) |
|
|
|
|
| Ulnar motor, right | ||||
| CMAP amplitude (mV) | 9.4 | 6 |
| 5.3 |
| Distal latency (m/s) |
|
|
|
|
| NCV (m/s) |
|
|
|
|
| F-wave latency (m/s) |
|
|
|
|
| Peroneal motor, right | ||||
| CMAP amplitude (mV) |
|
|
|
|
| distal latency (m/s) |
|
|
|
|
| NCV (m/s) |
|
|
|
|
| F-wave latency (m/s) |
|
|
|
|
| Tibial motor, right | ||||
| CMAP amplitude (mV) |
|
|
|
|
| distal latency (m/s) |
|
|
|
|
| NCV (m/s) | 49.6 | 46.9 |
|
|
| F-wave latency (m/s) |
| 49.3 |
|
|
| Median sensory, right | ||||
| SNAP amplitude (mV) |
|
|
|
|
| NCV (m/s) |
|
|
|
|
| Sural sensory, right | ||||
| SNAP amplitude (μV) | 17.8 |
|
|
|
| NCV (m/s) |
|
|
|
|
Abnormal values are shown in bold.
CMAP: compound muscle action potential, SNAP: sensory nerve action potential, NCV: nerve conduction velocity.
Figure 1Serial changes of compound motor action potentials (CMAPs) of the median and tibial nerves. (A) The first attack before the first intravenous immunoglobulin, (B) the second attack 8 weeks after the first attack, (C) the third attack 4 months after the second treatment, and (D) 6 months after appendectomy without immuno-modulating therapy.
Figure 2Pathologic findings of Crohn’s disease involving the appendix. The appendiceal wall is diffusely thickened by transmural lymphocytic infiltration and fibrosis, with scattered granulomas (A, arrows, H&E, original magnification x40). A large, well-formed, non-necrotizing granuloma is present in the mucosa (B, H&E, original magnification x200).
Cases of CIDP associated with Crohn's disease
|
|
|
|
|
|
|
|---|---|---|---|---|---|
| our case | 18/M | CA | −7 months | none | IVIG |
| 6 | 60/F | RR | 30 years | TNF-α antagonist (infliximab) | IVIG, prednisolone, azathioprine |
| 7 | 49/M | Q | 20 years | none | IVIG, plasmapheresis, fludarabine, methotrexate |
| 7 | 47/F | RR | 1 years | etanercept, prednisolone | IVIG, prednisolone, plasmapheresis |
| 7 | 50/M | RR | 23 years | azathioprine | IVIG, prednisolone |
| 8 | 36/M | CA | 4 years | mesalazine, metronidazole, ciprofloxacin, azathioprine | Plasmapheresis, prednisolone |
| 9 | 32/M | CA | 0 year | none (newly diagnosed) | IVIG, prednisolone, azathioprine |
| 10 | 63/F | CA | 0 year | none (newly diagnosed) | IVIG, prednisolone |
CA, currently active; Q, quiescent; RR, remitting/relapsing; UK, unkown; IVIg, intravenous immunoglobulin.